Abstract：Objective To evaluate the clinical factors associated with pathological complete response (pCR) after preoperative neoadjuvant chemoradiotherapy for rectal cancer. Methods A retrospective analysis was performed on the clinical data of 116 patients with rectal cancer, who underwent neoadjuvant chemoradiotherapy followed by radical surgery from January 2009 to December 2012. All patients received pelvic intensity-modulated radiotherapy (50 Gy/25 fractions) with concurrent fluorouracil-based chemotherapy and then underwent radical surgery 4—8 weeks later. The clinical factors associated with pCR or non-pCR were analyzed by Logistic regression. Results Of the 116 patients, 20(17.2%) achieved a pCR after neoadjuvant chemoradiotherapy. The univariate analysis showed that percentage of circumference of the rectal tube invaded by the tumor, preoperative serum carcinoembryonic antigen (CEA) level, T stage, N stage, distance from the anal verge, degree of tumor differentiation, and maximum tumor diameter were associated with pCR or non-pCR after neoadjuvant chemoradiotherapy for rectal cancer. The multivariate analysis revealed that percentage of circumference of the rectal tube invaded by the tumor, preoperative serum CEA level, and T stage were predictive factors for pCR or non-pCR after neoadjuvant chemoradiotherapy for rectal cancer. Conclusions Non-circumferential tumor (percentage of circumference of the rectal tube invaded by the tumor<75%), low CEA level, and early T stage before treatment may be associated with pCR after neoadjuvant chemoradiotherapy for rectal cancer.
Ayiguli·Hare,Palida·Apizi,Iskandar·Abulimiti et al. Analysis of clinical factors for pathological complete response after preoperative neoadjuvant chemoradiotherapy for rectal cancer[J]. Chinese Journal of Radiation Oncology, 2014, 23(1): 5-7.
[1] Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016):a multicentre, randomised trial[J]. Lancet,2009,373:811-820. [2] Roh MS, Colangelo LH, O′Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum:NSABP R-03[J]. J Clin Oncol,2009,27:5124-5130. [3] 陈纲,陈光,崔伟,等.新辅助放化疗治疗低位进展期直肠癌的临床研究[J].中国现代医药杂志,2011,13:25-27. [4] Maas M, Beets-tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer[J]. J Clin Oncol,2011,29:4633-4640. [5] Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer:a pooled analysis of individual patient data[J]. Lancet Oncol,2010,11:835-844. [6] Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival[J]. J Gastrointest Surg,2005,9:90-99. [7] Lee Sh, Hernandez de Anda E, Finne CO, et al. The effect of circumferential tumor location in clinical outcomes of rectal cancer patients treated with total mesorectal excision[J]. Dis Colon Rectum,2005,48:2249-2257. [8] Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual[M]. New York:Springer,2002. [9] Habr-Gama A, Perez RO, nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy:long-term results[J]. Ann Surg,2004,240:711-717. [10] Huh JW, Jung EJ, Park YA, et al. Preoperative chemoradiation followed by transanal excision for rectal cancer[J]. J Surg Res,2008,148:244-250. [11] Issa N, Murninkas A, Powsner E, et al.Long-term outcome of local excision after complete pathological response to neoadjuvant chemoradiation therapy for rectal cancer[J]. World J Surg,2012,36:2481-2487. [12] 林俊忠,潘志忠,曾智帆,等.影响直肠腺癌术前放疗后肿瘤病理完全缓解的多因素分析[J].癌症,2009,28:919-922. [13] Park YA, Sohn SK, Seong J, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer[J]. J Surg Oncol,2006,93:145-150. [14] Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer[J]. Ann Surg,2009,250:582-589. [15] Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer[J]. Cancer,2007,109:1750-1755. [16] Gérard JP, Azria D, Gourgou-Bourgade S,et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer[J]. J Clin Oncol,2012,30:4558-4565. [17] Kerr SF, Norton S, Glynne-Jones R,et al. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis[J].Br J Surg,2008,95:1534-1540. [18] Lim SB, Choi HS, Jeong SY,et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers[J]. Ann Surg,2008,248:243-251. [19] Sloothaak DA, Geijsen DE, van Leersum NJ,et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer[J].Br J Surg,2013,100:933-939. [20] de las Heras M, Arias F, del Moral-Avila R, et al. Multicenter phase Ⅱ clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer[J]. Clin Transl Oncol,2013,15:294-299. [21] Ghadimi BM, Grade M, Diflippantonio MJ, et al. effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy[J]. J Clin Oncol,2005,23:1826-1838. [22] Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression proiles[J]. Cancer Res,2006,66:3370-3374. [23] Garcia-Aguilar J, Chen Z, Smith DD, et al. IdentⅡcation of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer[J]. Ann Surg,2011,254:486-492.
2014, Vol. 23 
